Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy

Background: Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the ‘mixed responses’ frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	M. Willemsen, J. Bulgarelli, S.K. Chauhan, R.R. Lereim, D. Angeli, G. Grisendi, G. Krebbers, I. Davidson, J.A. Kyte, M. Guidoboni, R.M. Luiten, W.J. Bakker
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-12-01
Edice:	Immuno-Oncology and Technology
Témata:	melanoma AXL MITF DC vaccination immune checkpoint tumor heterogeneity
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S259001882400306X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!